Perbedaan Organon Pharma Indonesia Tbk. dan Teknologi Karya Digital Nusa Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Teknologi Karya Digital Nusa Tbk. diperdagangkan di Rp100 (kapitalisasi pasar 298,08 M, volume 24 jam 16,25 jt). Perbedaan utamanya: Teknologi Karya Digital Nusa Tbk. jauh lebih besar — sekitar 2,9× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | TRON | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 298,08 M |
Volume | — | 16,25 jt |
Lot | — | 162,51 rb |
Perputaran | — | 1,6 M |
Harga Rata-rata | — | 98,17 |
Nilai Transaksi | — | 1,6 M |
Harga Ekuilibrium Indikatif | — | 100 |
Volume Ekuilibrium Indikatif | — | 1,79 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →PT Teknologi Karya Digital Nusa Tbk (formerly PT Damai Harapan Sentosa) (the Entity) wasestablished based on Notarial Deed No. 25 dated January 7, 2011 of Tjoa Karina Juwita SH., Notaryin Jakarta. The Entity started its commercial operations in 2015. PT Teknologi Karya Digital Nusa Tbk is the parent entity, whereas David Santoso is the ultimate beneficial owner starting from 2020.
Selengkapnya di halaman TRON →